Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company focused on hereditary angioedema (HAE) and other rare diseases, and its news flow reflects this specialization. Company press releases frequently highlight regulatory milestones, clinical data, commercial performance, and strategic transactions related to its flagship product ORLADEYO® (berotralstat) and its broader rare disease pipeline.
Investors following BCRX news can expect regular updates on ORLADEYO, described as the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent HAE attacks. Recent announcements have covered U.S. Food and Drug Administration approval of an oral pellet formulation for pediatric patients aged 2 to <12 years, interim data from the APeX-P pediatric trial showing early and sustained reductions in attack rates, and presentations at major allergy and immunology congresses on the burden of HAE in children and caregivers.
BioCryst also issues news on its financial outlook and operating performance, including preliminary ORLADEYO net revenue, total revenue guidance that incorporates RAPIVAB® (peramivir injection), and non-GAAP operating expense expectations. These releases often explain how structural changes, such as the sale of the European ORLADEYO business, affect the company’s revenue mix and cost base.
Strategic and corporate developments are another major theme in BCRX news. The company has announced a definitive agreement to acquire Astria Therapeutics, Inc., with updates on regulatory clearances such as early termination of the Hart-Scott-Rodino waiting period and expected closing timelines. Additional news items include leadership changes, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and planned presentations at high-profile investor conferences.
For readers tracking BCRX, this news stream offers insight into BioCryst’s commercial execution in HAE, progress of its rare disease pipeline, evolving capital allocation, and key corporate events. Regularly reviewing these updates can help contextualize movements in BCRX stock and provide a clearer picture of the company’s strategic direction.
BioCryst Pharmaceuticals (BCRX) will present at the JMP Securities Hematology Summit on December 15, 2020, at 3:30 p.m. ET. This virtual event allows investors to access a live audio webcast of the presentation through the company's website. BioCryst focuses on developing oral, small-molecule medicines for rare diseases. Its approved product, ORLADEYO™, prevents HAE attacks and is currently under review in Japan and the EU. The company has several ongoing programs, including treatments for COVID-19 and other serious diseases.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has secured $325 million in funding, including $250 million at closing, to bolster the launch of ORLADEYO™ (berotralstat) for hereditary angioedema (HAE) and advance its oral Factor D inhibitor, BCX9930. The financing comprises a $125 million upfront payment from Royalty Pharma with an 8.75% royalty structure on sales up to $350 million, and a $200 million credit facility from Athyrium Capital. The funds will also enable BioCryst to repay existing debt and expand its clinical trials amid promising early data for BCX9930.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced promising preclinical data for BCX9930, an oral Factor D inhibitor aimed at treating paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases. The data, presented at the 62nd ASH Annual Meeting, showed complete in vitro blockade of hemolysis in PNH erythrocytes. BCX9930 demonstrated specificity for the alternative pathway, with significant suppression observed in primates. The FDA has granted Fast Track status and Orphan Drug designation for BCX9930.
BioCryst Pharmaceuticals (BCRX) announced FDA approval for ORLADEYO™ (berotralstat), an oral, once-daily prophylactic treatment for hereditary angioedema (HAE) in patients aged 12 and older. The pivotal Phase 3 APeX-2 trial showed a significant reduction in HAE attacks, from 2.9 to 1.0 per month after 48 weeks. With EMPOWER Patient Services, access to therapy is streamlined, providing dedicated support for patients. ORLADEYO represents a critical advancement, reducing treatment burden compared to existing injectable therapies.
BioCryst Pharmaceuticals (BCRX) announced the granting of inducement stock options to 13 newly-hired employees on November 30, 2020. The total of 260,500 shares were awarded at an exercise price of $5.11, equal to the closing price on the grant date. These options vest in four equal annual installments starting one year from the grant date and have a 10-year term. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of BioCryst's Inducement Equity Incentive Plan.
BioCryst Pharmaceuticals (BCRX) announced that the APeX-J trial results, published in the journal Allergy, showed berotralstat significantly reduces the rate of hereditary angioedema (HAE) attacks compared to placebo. The trial's primary endpoint was met with a p-value of 0.003, confirming the drug's safety and tolerability. Berotralstat is set to be the first approved prophylactic therapy for HAE in Japan, with its new drug application currently under review and a decision expected in December 2020.
BioCryst Pharmaceuticals (Nasdaq:BCRX) announced its participation in the Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences, both held virtually. The Evercore presentation is scheduled for December 2, 2020, at 12:35 p.m. ET. Investors can access a pre-recorded presentation on November 23, 2020, via the company’s website. BioCryst is focused on developing innovative treatments for rare diseases, including ORLADEYO for hereditary angioedema and BCX9930 for complement-mediated diseases.
BioCryst Pharmaceuticals presented new clinical data on berotralstat for hereditary angioedema (HAE) at the 2020 ACAAI meeting. The APeX-2 trial showed a significant reduction in attack rates over 48 weeks, with patients reporting a mean monthly attack rate drop from 2.5 to 0.6. Additionally, treatment improved patient satisfaction, reflected by a 26-point increase in the Treatment Satisfaction Questionnaire scores. Quality of life also improved, with 77% of patients exceeding the minimal clinically important difference. Berotralstat is an investigational oral treatment pending FDA approval.
BioCryst Pharmaceuticals (Nasdaq:BCRX) shared data at the 2020 ACAAI meeting, highlighting the significant treatment burden faced by hereditary angioedema (HAE) patients. Key findings indicated that 86% of patients desire easier medication administration, with 58% expressing fatigue over injections. A majority of caregivers identified challenges in learning to administer treatments, while 94% of physicians acknowledged the need for novel therapies. This data emphasizes an unmet need for improved HAE management and the potential for enhanced patient-physician dialogue to address treatment concerns.
BioCryst Pharmaceuticals (BCRX) announced that preclinical data on BCX9930, an oral Factor D inhibitor, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting on December 6, 2020. The abstract is available on the ASH website. BCX9930 is a novel oral treatment for complement-mediated diseases, currently in Phase 1 clinical development for Paroxysmal Nocturnal Hemoglobinuria (PNH). The FDA has granted Fast Track and Orphan Drug designations for the drug. Preliminary results show that BCX9930 has been safe and well tolerated with significant biomarker improvements in PNH patients.